Key Issues and Potential Solutions for Understanding Healthcare Preference Heterogeneity Free from Patient-Level Scale Confounds Catharina G. M. Groothuis-OudshoornTerry N. FlynnMark Oppe Commentary 25 April 2018 Pages: 463 - 466
Symposium Title: Preference Evidence for Regulatory Decisions Juan Marcos GonzalezF. Reed JohnsonHolly Peay Commentary 30 May 2018 Pages: 467 - 473
Accounting for Scale Heterogeneity in Healthcare-Related Discrete Choice Experiments when Comparing Stated Preferences: A Systematic Review Stuart J. WrightCaroline M. VassKatherine Payne Systematic Review 28 February 2018 Pages: 475 - 488
Themes that Determine Quality of Life in Patients with Peripheral Arterial Disease: A Systematic Review Ahmed AberElizabeth LumleyJonathan Michaels Systematic Review 08 May 2018 Pages: 489 - 502
Patient Preferences for Managing Insomnia: A Discrete Choice Experiment Janet M. Y. CheungDelwyn J. BartlettTracey-Lea Laba Original Research Article 03 March 2018 Pages: 503 - 514
The Parker Model: Applying a Qualitative Three-Step Approach to Optimally Utilize Input from Stakeholders When Introducing New Device Technologies in the Management of Chronic Rheumatic Diseases Tanja S. JørgensenMarie SkougaardLars Erik Kristensen Original Research Article Open access 11 June 2018 Pages: 515 - 526
Patient Perspective on Acute Intermittent Porphyria with Frequent Attacks: A Disease with Intermittent and Chronic Manifestations Amy SimonFarrah PompilusPatrick Marquis Original Research Article Open access 19 June 2018 Pages: 527 - 537
Adaptation, Acceptance and Adaptive Preferences in Health and Capability Well-Being Measurement Amongst Those Approaching End of Life Joanna CoastCara BaileyPhilip Kinghorn Original Research Article 09 May 2018 Pages: 539 - 546
Understanding How Chorea Affects Health-Related Quality of Life in Huntington Disease: An Online Survey of Patients and Caregivers in the United States Eileen Mack ThorleyRavi G. IyerNoelle E. Carlozzi Original Research Article Open access 11 May 2018 Pages: 547 - 559
Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir, and Lamivudine David WohlAmanda ClarkeErin Quirk Original Research Article Open access 29 June 2018 Pages: 561 - 573